$111.370
-1.682 (-1.51%)Zum Schluss
Umsatzquellen von VCTR
Victory Capital Holdings, Inc. (VCTR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Investment management fees-Mutual funds (Victory Funds), accounting for 44.8% of total sales, equivalent to $195.21M. Other significant revenue streams include Investment management fees-Separate accounts and other vehicles and Investment management fees-Performance-based fees-Separate accounts and other vehicles. Understanding this composition is critical for investors evaluating how VCTR navigates market cycles within the Investment Management & Fund Operators industry.
Profitabilität und Margen von VCTR
Evaluating the bottom line, Victory Capital Holdings, Inc. maintains a gross margin of 84.25%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 46.51%, while the net margin is 32.02%. These profitability ratios, combined with a Return on Equity (ROE) of 14.69%, provide a clear picture of how effectively VCTR converts its operational activities into shareholder value.
VCTR im Vergleich zur Peergroup
In the context of the broader market, VCTR competes directly with industry leaders such as CIGI and HQY. With a market capitalization of $7.42B, it holds a significant position in the sector. When comparing efficiency, VCTR's gross margin of 84.25% stands against CIGI's 35.83% and HQY's 66.05%. Such benchmarking helps identify whether Victory Capital Holdings, Inc. is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von Victory Capital Holdings Inc
Victory Capital has shown strong financial performance with a recent net income of $139.4 million in Q2 2026, and a gross margin of 84.25%, indicating efficient operations and profitability.
Financials
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.